Cialis ® (tadalafil) tablets

2.5 mg, 5 mg, 10mg, 20 mg tablets

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

Urinary Flow Rate Effects of CIALIS (tadalafil) in Men with BPH

Mean Qmax increased from baseline in the CIALIS 5 mg once daily and placebo groups; however, these changes were not significantly different between groups.

The efficacy and safety of Cialis® (tadalafil) for once-daily use was evaluated in three 12-week randomized, double-blind, placebo-controlled, multicenter trials:

  • studies I and II in men with signs and symptoms of benign prostatic hyperplasia (BPH‑LUTS), and

  • study III in men with both erectile dysfunction and BPH.


Maximum urinary flow rate (Qmax), an objective measure of urine flow, was assessed as a secondary efficacy endpoint in study I and as a safety endpoint in studies II and III.

Mean Qmax increased from baseline in both the tadalafil and placebo groups in all 3 studies. However, within each trial, the changes in Qmax were not significantly different between treatment with placebo and tadalafil 5 mg.

Reference

CIALIS [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.



Date of Last Review: April 26, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical